Skip to main content

CVM

Stock
Health Care
Biotechnology

Performance overview

CVM Price
Price Chart

Forward-looking statistics

Beta
0.78
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Company info

SectorHealth Care
IndustryBiotechnology
Employees29
Market cap$70.4M

Fundamentals

Enterprise value$15.5M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity131.68

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$12.30
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$540K
Put-call ratio

Macro factor sensitivity

Growth-3.9
Credit+5.1
Liquidity+7.2
Inflation-5.3
Commodities-4.1
Interest Rates-2.4

Valuation

Dividend yield0.00%
PEG Ratio-5.66
Price to sales
P/E Ratio-5.66
Enterprise Value to Revenue
Price to book0.88

Upcoming events

Next earnings dayJanuary 14, 2025
Next dividend day
Ex. dividend dayAugust 28, 1996

News

Why CEL-SCI Shares Are Getting Hammered Today

CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector.

Benzinga (June 30, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free